Surgical oncologist Mr Myles Smith and colleagues recently had a review published into the oncologic outcomes of surgically managed primary pelvic soft tissue sarcoma; tumour biology or surgical constraints of the true pelvis. This was featured in the European Journal of Surgical Oncology.
The review sought to determine if there was a difference between outcomes for surgically managed patients that had localised and extended pelvic soft tissue sarcomas. It compared the results of sixty seven patients between 2012 and 2020.
The review examined pre-treatment scans and surgical notes – along with oncologic endpoints including resection margins, recurrence rates, when the patients were disease-free and their overall survival rates.
The review concluded that the disease extent does not affect oncologic outcomes. However, a complete oncologic resection is key to determining the risk of local recurrence, and tumour grade and metastatic relapse are both key to survival rates.
You can read the review here – https://www.ejso.com/article/S0748-7983(22)01351-8/fulltext